myriamed – the drug development accelerator

Separating the pharmacological wheat from the chaff is the primary goal of myriamed. Our proprietary human cell and engineered tissue models allow for the simulation of health and disease in the dish. Our platform technologies find broad applications in early stages of drug discovery and refinement of the most promising therapeutic candidates.

Information gained from our advanced engineered tissue models can assist drug developers in defining safe and effective doses for first in human studies. Reduction in attrition rate and acceleration of clinical translation of the most promising therapeutic candidates to address pressing unmet medical needs is what we strive for.

SERVICES

Click below to learn more about the myriamed platform portfolio.

MYR- 6 values

Ownership

We have a strong academic and entrepreneurial background. It is our passion to enable our customers to address unmet medical needs quickly, safely, efficiently, and cost-effectively.

Innovation

We constantly innovate our technology platforms. We respect freedom of ideas and combine both internal and external technology and expertise from around the world to find best solutions.

Communications

We welcome diverse opinions and adverse views presented in a constructive manner. We strive to openly, fairly, and clearly communicate the rationale for our decisions.

Trust

We believe in trusting people internally and externally to quickly deliver solutions to complex system issues. Trust is enhanced by reliability, quality, and honesty.

Success

We value success achieved under high ethical standards and environmental consciousness over success gained at the expense of others. We strive to be responsive to changes in technology and science impacting the needs of our customers.

Financial goal

is healthy and sustainable growth. The long-term prospect of success always lies at the heart of our strategies.

NEWS

2018-09-30 13:24

myriamed presented its technologies at the 2018 Safety Pharmacology Society Meeting in Washington, DC

2018-09-30 13:24
2017-09-24 14:59

myriamed presented its innovative platform technologies at the 2017 Safety Pharmacology Society Meeting in Berlin, Germany

2017-09-24 14:59
2017-09-13 15:00

MBM ScienceBridge GmbH vermittelt Lizenzvertrag zwischen der Universitätsmedizin Göttingen (UMG) und dem Hamburger Biotech-Unternehmen Tissue Systems Holding GmbH...

2017-09-13 15:00

„E Pluribus Unum (out of many - one)“

Separating the pharmacological wheat from the chaff to enhance safety and efficacy of new molecular entities (NMEs) is the primary goal of myriamed. Our unique strengths are high quality secondary screens based on proprietary tissue engineered organ platforms. We offer our support to the pharmaceutical and biotech industry at an early stage of drug development to improve the attrition rate and enhance cost-effectiveness of drug development.

Get in touch with our team!

Dr. Eriona Heta

Research and Development specialist with >5 years of experience in myriamed platforms and genetic engineering of human pluripotent stem cells. Dr. Heta obtained her PhD in the Institute of Pharmacology and Toxicology at the University Medical Center Göttingen.

Get in contact

Franz Kirchmeir

Managing Director

Business professional with microbiological background and extensive knowledge in global business development, strategic management and team leadership with over 20 years experience and strong focus on the Biotechnology and Life Science industry.

Get in contact

Copyright 2018 Seaside Media. All Rights Reserved.